Development of a Neutralization Assay for Nipah Virus Using Pseudotype Particles

Date
2009-09-01
Authors
Tamin, Azaibi
Harcourt, Brian
Roth, James
Lo, Michael
Roth, James
Wolf, Mike
Lee, Benhur
Weingertl, Hana
Audonnet, Jean-Christophe
Bellini, William
Rota, Paul
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Authors
Roth, James
Person
Research Projects
Organizational Units
Journal Issue
Series
Department
Veterinary Microbiology and Preventive Medicine
Abstract

Nipah virus (NiV) and Hendra virus (HeV) are zoonotic paramyxoviruses capable of causing severe disease in humans and animals. These viruses require biosafety level 4 (BSL-4) containment. Like other paramyxoviruses, the plaque reduction neutralization test (PRNT) can be used to detect antibodies to the surface glycoproteins, fusion (F) and attachment (G), and PRNT titers give an indication of protective immunity. Unfortunately, for NiV and HeV, the PRNT must be performed in BSL-4 containment and takes several days to complete. Thus, we have developed a neutralization assay using VSV pseudotype particles expressing the F and G proteins of NiV (pVSV-NiV-F/G) as target antigens. This rapid assay, which can be performed at BSL-2, was evaluated using serum samples from outbreak investigations and more than 300 serum samples from an experimental NiV vaccination study in swine. The results of the neutralization assays with pVSV-NiV-F/G as antigen showed a good correlation with those of standard PRNT. Therefore, this new method has the potential to be a rapid and cost-effective diagnostic method, especially in locations that lack high containment facilities, and will provide a valuable tool for basic research and vaccine development.

Comments

This article is from Journal of Virological Methods 160 (2009): 1, doi:10.1016/j.jviromet.2009.02.025.

Description
Keywords
Citation
DOI
Collections